DiscoverEagle's Eye View: Your Weekly CV Update From ACC.orgBMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement
BMI, Adiposity & Tirzepitide and HFpFF;  BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement

BMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement

Update: 2025-07-30
Share

Description

In this week’s View, Dr. Eagle looks at the SUMMIT trial and considers how body mass index (BMI) and central adiposity affect tirzepatide outcomes for heart failure with preserved ejection fraction (HFpEF). He then discusses bicuspid aortic valves type 0 (BAV-0) and its association with better long-term prognosis in patients with severe aortic stenosis (AS) undergoing tricuspid aortic valve replacement (TAVR). Finally, Dr. Eagle examines long-term risk of infective endocarditis and why it is significantly higher for mitral valve (MV) replacement versus repair. 

 
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

BMI, Adiposity & Tirzepitide and HFpFF;  BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement

BMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement